MyoKardia, Inc. (NASDAQ:MYOK)‘s stock had its “buy” rating reissued by investment analysts at BMO Capital Markets in a research report issued on Tuesday. They presently have a $45.00 target price on the biotechnology company’s stock. BMO Capital Markets’ target price points to a potential upside of 24.31% from the company’s current price.

A number of other analysts have also weighed in on the stock. ValuEngine raised shares of MyoKardia from a “sell” rating to a “hold” rating in a research note on Monday. Wells Fargo & Company reissued an “outperform” rating and set a $48.00 target price (up from $31.00) on shares of MyoKardia in a research note on Monday. TheStreet raised shares of MyoKardia from a “d+” rating to a “c” rating in a research note on Thursday, July 6th. Cowen and Company upped their price target on shares of MyoKardia from $28.00 to $56.00 in a research report on Monday. Finally, Zacks Investment Research downgraded shares of MyoKardia from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $37.60.

Shares of MyoKardia (NASDAQ:MYOK) traded up 15.10% during trading on Tuesday, hitting $36.20. The company’s stock had a trading volume of 3,700,943 shares. The company’s market cap is $1.14 billion. MyoKardia has a 52 week low of $10.55 and a 52 week high of $36.75. The firm’s 50 day moving average price is $14.29 and its 200-day moving average price is $13.21.

MyoKardia (NASDAQ:MYOK) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.04. MyoKardia had a negative net margin of 39.44% and a negative return on equity of 15.27%. The business had revenue of $5.60 million for the quarter, compared to the consensus estimate of $6.73 million. During the same period in the prior year, the company earned ($0.37) EPS. MyoKardia’s quarterly revenue was up 60.0% on a year-over-year basis. On average, analysts predict that MyoKardia will post ($1.63) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/08/bmo-capital-markets-reaffirms-buy-rating-for-myokardia-inc-myok.html.

In related news, insider Anastasios Gianakakos sold 32,988 shares of the stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $15.00, for a total transaction of $494,820.00. Following the completion of the sale, the insider now owns 541,151 shares in the company, valued at approximately $8,117,265. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 46.10% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. Highbridge Capital Management LLC bought a new stake in MyoKardia during the first quarter valued at $136,000. Trexquant Investment LP boosted its stake in shares of MyoKardia by 134.5% in the first quarter. Trexquant Investment LP now owns 37,987 shares of the biotechnology company’s stock valued at $500,000 after buying an additional 21,787 shares in the last quarter. Norges Bank acquired a new stake in shares of MyoKardia during the fourth quarter valued at approximately $869,000. Point72 Asset Management L.P. acquired a new stake in shares of MyoKardia during the first quarter valued at approximately $1,546,000. Finally, Wellington Management Group LLP boosted its stake in shares of MyoKardia by 12.5% in the first quarter. Wellington Management Group LLP now owns 3,154,734 shares of the biotechnology company’s stock valued at $41,485,000 after buying an additional 349,768 shares in the last quarter. Hedge funds and other institutional investors own 47.74% of the company’s stock.

About MyoKardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.